These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27543314)

  • 1. DNA repair mechanisms and their clinical impact in glioblastoma.
    Erasimus H; Gobin M; Niclou S; Van Dyck E
    Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
    Lozinski M; Bowden NA; Graves MC; Fay M; Tooney PA
    Cell Oncol (Dordr); 2021 Oct; 44(5):961-981. PubMed ID: 34057732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
    Annovazzi L; Caldera V; Mellai M; Riganti C; Battaglia L; Chirio D; Melcarne A; Schiffer D
    Int J Oncol; 2015; 46(6):2299-308. PubMed ID: 25892134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
    Messaoudi K; Clavreul A; Lagarce F
    Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Insights on EGFR Signaling Pathways in Glioma.
    Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
    Ferri A; Stagni V; Barilà D
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways.
    Chaudhry MA; Sachdeva H; Omaruddin RA
    DNA Cell Biol; 2010 Sep; 29(9):553-61. PubMed ID: 20380575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broken beyond repair. Damaging DNA in glioblastoma cells with radiation and camptothecin.
    Darzynkiewicz Z
    Cancer Biol Ther; 2008 Mar; 7(3):374-5. PubMed ID: 18614857
    [No Abstract]   [Full Text] [Related]  

  • 12. The DNA methylome of glioblastoma multiforme.
    Martinez R; Esteller M
    Neurobiol Dis; 2010 Jul; 39(1):40-6. PubMed ID: 20064612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key concepts in glioblastoma therapy.
    Bartek J; Ng K; Bartek J; Fischer W; Carter B; Chen CC
    J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):753-60. PubMed ID: 22396442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
    Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E; Tosoni A; Pozzati E; Brandes AA
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
    Johannessen TC; Bjerkvig R
    Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GBM radiosensitizers: dead in the water…or just the beginning?
    Bindra RS; Chalmers AJ; Evans S; Dewhirst M
    J Neurooncol; 2017 Sep; 134(3):513-521. PubMed ID: 28762004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in epigenetic glioblastoma therapy.
    Lee DH; Ryu HW; Won HR; Kwon SH
    Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.